NCT04564027 2025-08-29A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced CancerAstraZenecaPhase 2 Completed54 enrolled 16 charts
NCT02937818 2024-06-07A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung CancerAstraZenecaPhase 2 Completed72 enrolled 29 charts